BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Collategene beperminogene perplasmid: Phase I/IIa data

In an open-label, Japanese Phase I/IIa trial in 22 patients, 2 injections of either 2 or 4 mg Collategene beperminogene perplasmid showed no serious adverse events, including peripheral edema, were observed 6 months after gene transfer. At 2...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >